Nucryst trial of dermatitis cream fails to meet endpoint

By Lisa Kerner

Charlotte, N.C., Sept. 20 - Nucryst Pharmaceuticals Corp. said preliminary top line results from its phase 2 safety and efficacy trial of NPI 32101 in a topical cream formulation, in children and adolescents with atopic dermatitis, showed no significant difference in disease clearance among the three treatment groups.

The treatment groups included 2% NPI 32101 cream, 1% NPI 32101 cream or a placebo cream twice daily for 12 weeks.

In addition, the success rates of both 2% and 1% NPI 32101 creams were statistically identical to that of the placebo.

The study failed to meet its primary efficacy endpoint; however, treatment with NPI 32101 cream was well-tolerated.

Based on preclinical results in a variety of in vitro and in vivo models, the Wakefield, Mass., medical products company said it will continue to develop NPI 32101 for a variety of disease conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.